...
首页> 外文期刊>The journal of gene medicine >Osteosarcoma cell lines display variable individual reactions on wildtype P53 and Rb tumour-suppressor transgenes
【24h】

Osteosarcoma cell lines display variable individual reactions on wildtype P53 and Rb tumour-suppressor transgenes

机译:骨肉瘤细胞系对野生型P53和Rb肿瘤抑制剂转基因表现出可变的个体反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background One of the most widely studied gene therapeutic strategies for cancer is the introduction of tumour-suppressor genes - generally p53 - into the target cells. As the genes of p53 and/or retinoblastoma (Rb) are mutated in the major part of osteosarcomas (OS), we aimed to study the effect of p53 and Rb transgenes on a panel of five different osteosarcoma cell lines.Methods OS cell lines were transduced by adenoviral vectors delivering the transcription units of the wildtype p53 and the Rb gene. Effects of the transgenes alone and at additional cytostatic stress were studied by proliferation, alive/dead and cell cycle assays.Results The individual cells lines displayed divergent reactions to p53-or Rb-transgene delivery reaching from cell death (SaOs-2, U2OS at p53 transduction) over stopped or lowered cell division (MG-63, K-HOS, SJSA-1 at p53 and Rb transduction) to nearly unhindered cell growth (U2OS at Rb transduction). In those OS cell lines reacting with lowered cell division to p53 or Rb delivery, cytostatics only moderately intensified the transgene effects. Surprisingly, these reactions were apparently not dependent on the functional status of the cellular p53 and/or Rb genes or on differences in the infectability of the cell lines by the adenoviral vectors. Most interestingly, the respective effects of the p53 or Rb transgenes were not multiplied by simultaneous transduction of both tumour-suppressor genes.Conclusions The application of wildtype tumour-suppressor gene therapy on genetically variable osteosarcomas may be efficient only in yet not identified genetic subgroups of this turnout entity. Hyperactive tumour-suppressor transgenes could be an alternative. Copyright (c) 2004 John Wiley C Sons, Ltd.
机译:背景技术研究最广泛的癌症基因治疗策略之一是将肿瘤抑制基因(通常为p53)引入靶细胞。由于p53和/或视网膜母细胞瘤(Rb)的基因在骨肉瘤(OS)的主要部分发生了突变,因此我们旨在研究p53和Rb转基因对五种不同的骨肉瘤细胞系的影响。通过传递野生型p53和Rb基因转录单位的腺病毒载体转导。通过增殖,存活/死亡和细胞周期试验研究了单独转基因的作用以及在额外的抑制细胞生长的压力下的结果。结果单个细胞系对从细胞死亡(SaOs-2,U2OS到p53转导)停止或降低的细胞分裂(MG53,K-HOS,SJSA-1在p53和Rb转导)到几乎不受阻碍的细胞生长(在Rb转导时为U2OS)。在那些OS细胞系与降低的细胞分裂反应到p53或Rb传递中,细胞抑制剂仅适度增强了转基因作用。令人惊讶地,这些反应显然不依赖于细胞p53和/或Rb基因的功能状态,也不依赖于腺病毒载体对细胞系的可感染性的差异。最有趣的是,p53或Rb转基因的各自作用并没有同时被两个肿瘤抑制基因的转导所加。这个投票实体。过度活跃的肿瘤抑制基因可能是另一种选择。版权所有(c)2004 John Wiley C Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号